Alpha Cognition Inc.

and welcome to the Alpha Cognition first quarter earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Henry Du, Interim CFO. You may begin.

Thanks, Kate. Good afternoon, everyone, and thank you for joining us today for Outlook Ignition's first quarter 2026 financial results conference call. Today, after the close of market, the company issued a press release announcing these results. On the call with me today are Outlook Ignition's Chief Executive Officer, Michael McFadden, and Chief Operating Officer, Lauren D'Angelo. Today's call is being made available via the investor section of the company's website at www.outlookignition.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking statements reflect Alpha Cognition's current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the risk factor section of the company's latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements. For the benefit of those of you who may be listening to the replay, this call is being held and recorded on May 14, 2026. Since then, the company may have made additional announcements related to the topics discussed. Please reference the company's most recent press releases and current filings with the SEC. Alpha Cognition declines any obligation to update these forward-looking statements, except as required by applicable security laws. I'll now turn the call over to Michael. Michael?

Thank you, Henry. Good afternoon, everyone, and welcome to today's call. The first quarter of 2026 represents our fourth full quarter of commercialization for Zunvell, the first new oral Alzheimer's treatment approved in more than 15 years, and the quarter was a strong one. We delivered 40% quarter-over-quarter revenue growth, acceleration in prescriber adoption, advanced strategic priorities across our clinical programs, We strengthened our intellectual property portfolio, and the company further built out our organization as we enter the expansion phase for Zumwale. We continue to execute with discipline and confidence, and I believe this quarter demonstrates that Zumwale's commercial industry is tracking well with our internal expectations. In Q1 2026, we generated net total product revenues of $3.5 million, a 40% sequential increase over Q4 2025. While we are very pleased with Zimbel's trajectory, we're still at only the start of Zimbel's commercial phase. The company remains optimistic and believe we will continue to see signs of sustained product performance and adoption within the long-term care segment. Looking at Q1, we saw growth in the quarter, with March delivering our strongest month of demand sales, and April is stronger than March. Overall, we believe we're on track with our 2026 strategic priorities and we continue to expect to achieve operating profitability in 2027. On the adoption side, our prescription KPIs remain strong. Our bottles dispensed grew 23% over Q4. Our HCP riders grew 23% over year-end 2025, and we're on track to achieve our 2026 goal of approximately 2,000 prescribers. Our call-down prescribers expanded 93% quarter-over-quarter, and our nursing homes with dumbbell prescriptions grew 25%. Additionally, the commercial team built out its 60-person customer-facing team in the quarter. We saw an added experience marketing and payer engagement capabilities to the team. And last month, we strengthened our board of directors with the addition of a new independent board member, Bethany Sensenig. We looked to her experience to help build out alpha cognition strategy and for her to provide financial governance for the company. Turning to our clinical programs, we have three active real-world studies underway, which we believe will strengthen Zumbel's positioning with payer and healthcare providers. Beacon, our real-world effectiveness study evaluating Zumbel in long-term care residents with Alzheimer's disease, will complete enrollment this quarter. The company will report top-line data from Beacon no later than early third quarter, an acceleration from our prior expectation of late Q4. Converge, our retrospective data analysis evaluating tolerability, dosing, polypharmacy, and adverse events in long-term care, initiates in Q2 as planned, and we expect top-line data from this trial in Q3 of 2026. We expect both Beacon and Converge to provide the company numerous publication opportunities over the coming year. Resolve, our phase four outpatient study, will also initiate this quarter. This study will provide additional data regarding tolerability and efficacy in treating behaviors associated with Alzheimer's disease in the outpatient setting. On the intellectual property front, the U.S. Admin Office issued two patents to provide additional protection for Zumbel. A new patent covering dosage regiments for benzgalantamine was given in February, and a second covering the use of benzgalantamine for treating traumatic brain injury was issued in March. Both patents extend protection of the product through 2045. And the TBI market, by the way, represents an addressable opportunity for the company estimated at approximately $14 billion. Regarding our sublingual formulation program, we will initiate a comparative pharmacokinetic study versus our tablet this quarter. The PK data, should it show equivalence, could be sufficient to advance the sublingual formulation to the clinic. With respect to our ex-U.S. partnership, CMS Pharma continues to advance the regulatory process across multiple countries in Asia, and we anticipate two strategic product approvals in 2026. From a financial perspective, the company's operating spend of approximately $10,000 reflects a deliberate investment in our commercial capabilities and in studies that support our positioning with healthcare providers and payers. I want to be direct about the way we're thinking about our investment phase. Our net loss this quarter reflects the company scaling our efforts intentionally. We're deploying capital against our highest return opportunities in the business. including expanding prescriber reach, building real-world evidence to support Zunvel, and unlocking additional payer access. These are investments that will drive the company to achieve operating profitability in 2027 and beyond, and we continue to remain on track with these targets. Henry will now review the financials in detail, and Lauren will provide a comprehensive commercial update after Henry concludes his comments. Henry?